Retatrutide and Cagrilintide, when combined, offer a synergistic approach to weight management and metabolic health by targeting multiple physiological pathways involved in appetite regulation, energy balance, and glucose control. Retatrutide, a triple agonist acting on GLP-1, GIP, and glucagon receptors, has demonstrated significant weight loss in clinical trials, with up to 24% body weight reduction in a 48-week phase 2 study.
 Cagrilintide, an amylin analog, enhances satiety and slows gastric emptying through amylin receptors, contributing to dose-dependent weight reduction.
 The combination is theorized to amplify benefits by integrating amylin’s satiety effects with Retatrutide’s multi-hormonal actions, potentially surpassing the efficacy of single-agent therapies.
Retatrutide activates GLP-1, GIP, and glucagon receptors, leading to reduced appetite, improved insulin sensitivity, enhanced energy expenditure, and significant weight loss.
Cagrilintide mimics amylin, promoting satiety and slowing gastric emptying, which helps reduce food intake and supports weight management.
Preclinical and early clinical data suggest that combining Cagrilintide with a GLP-1 agonist like Retatrutide may produce synergistic effects, improving weight loss outcomes beyond monotherapy.
The combination may also improve cardiometabolic markers such as blood pressure, lipid profiles, HbA1c, fasting glucose, and hepatic fat, with Retatrutide showing normalization of liver fat in patients.
While Retatrutide monotherapy has shown up to 24% weight loss, Cagrilintide alone has led to 6–10.8% weight loss, and its combination with semaglutide (CagriSema) achieved over 15% weight loss, indicating strong potential for synergy.
Both agents are administered via once-weekly subcutaneous injection, with gastrointestinal side effects such as nausea and constipation being common but generally manageable with gradual dose titration.
As of January 2026, no peer-reviewed human trials have yet tested the Retatrutide and Cagrilintide combination as a single regimen, though related combinations (e.g., cagrilintide + semaglutide) show promising results.
The blend is currently used in research settings for studying appetite, energy balance, and metabolic regulation, with quality control and proper reconstitution being essential for laboratory use.